Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Thyroid Neoplasms 1Skin Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 3Trastuzumab 3Sunitinib 3Magnetic Resonance Spectroscopy 3selpercatinib 2palbociclib 2lenvatinib 2larotrectinib 2belinostat 2Surveys and Questionnaires 2Specimen Handling 2Sirolimus 2Nivolumab 2Immunoglobulin G 2Fluorodeoxyglucose F18 2Disulfides 2Biopsy 2vandetanib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1tipifarnib 1temsirolimus 1spartalizumab 1sapanisertib 1romidepsin 1relatlimab 1regorafenib 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × IT-101 × Breast × Clear all
NCT00333502 2020-05-28

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

Lumos Pharma

Phase 1/2 Completed
62 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Skin Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡